| Summary: | Background. ALL is the most common malignancy in children. Primary therapy of
ALL is chemotherapy. There are many chemotherapy agents are used. Some groups
of them such as mtx, daunorubicine and doxorubicine produce ROS which is part of
free radicals. ROS can reduce levels of antioxidant levels including SOD in the
body. The decrease of SOD levels can cause DNA, lipid and protein damage resulting
adverse effects until failure of treatment.
Objective. To determine the impact of mtx and daunorubicine/doxorubicine
cumulative dose on SOD levels in childhood ALL
Methods. A retrospective cohort study was conducted on childhood ALL
undergoing chemotherapy in Dr. Sardjito General Hospital on october 2011. Subjects
were ALL patients aged 0-18 years and have completed the induction phase and their
parents have signed proxy concent. Exclution criteria were patients with incomplete
data. Risk factors for decreased SOD levels was analyzed by cox regression, hazard
ratio to determine the relationship with a significance level of <0,05
Results. Of forty patients enrolled, bivariate analysis showed that mtx�3000 mg/m2
could decrease SOD levels (HR 9.959 CI95% 2.819-35.183
|
|---|